Chimeric small molecule therapeutics

Last updated

Chimeric small molecule therapeutics are a class of drugs designed with multiple active domains to operate outside of the typical protein inhibition model. While most small molecule drugs inhibit target proteins by binding their active site, chimerics form protein-protein ternary structures to induce degradation or, less frequently, other protein modifications.

Contents

Background

Small molecule drugs, compounds typically <1 kD in mass, comprise a large portion of the therapeutic market. [1] These drugs usually operate by agonizing or antagonizing the active site on a disease-linked protein of interest, though allosteric regulation is possible. [2] With an estimated 93% of the human proteome lacking druggable binding sites, [3] methods have been developed to modulate protein activity through binding of any available site rather than only the active site. These drugs contain a target protein binding warhead in addition to a linker-separated active domain. This domain may recruit a second protein to the proximity, induce protease-mediated degradation, or recruit a kinase for directed phosphorylation, among other functions. [4] These drugs expand both the mechanism of action for small molecule therapeutics and the pool of potential protein targets. [5]

Proteolysis-targeting chimeras

Mechanism of an E3 ligase-targeting PROTAC Proteolysis targeting chimera mechanism.svg
Mechanism of an E3 ligase-targeting PROTAC

Proteolysis-targeting chimeras (PROTACs) were first reported by Kathleen Sakamoto, Craig Crews, and Raymond Deshaies in 2001. A chimeric molecule consisting of ovalicin (a MetAP-2 small molecule inhibitor) and IκBα phosphopeptide (a recruiter of the SCFβ-TRCP E3 ligase complex) separated by a linker was constructed and shown to induce MetAP-2 degradation in in vitro cell models. Further study confirmed that E3 ligase-mediated ubiquitination and subsequent proteasome degradation was responsible for reduced MetAP-2 levels. [6] Continued work on this system by Craig Crews and others has expanded the potential pool of E3 ligases and degradation targets with Arvinas Inc. founded in 2013 to bring PROTAC drugs to market. [7] As of April 2023, Arvinas has one drug in Stage 3 clinical trials (ARV-471, an estrogen receptor degrader), and two drugs in Stage 2 clinical trials (androgen receptor degraders ARV-110 and ARV-766) for treatment of breast and prostate cancer, respectively. [8] Arvinas released Phase 2 clinical trial results for ARV-471 in December, 2022 reporting a clinical benefit rate of 40% in CDK4/6 inhibitor-pretreated patients and an absence of dose-limiting toxicities. [9]

Hydrophobic tag degradation

Hydrophobic tag degraders contain a binding domain in addition to a linker-separated hydrophobic moiety, such as adamantyl, to induce protein degradation. As exposed hydrophobicity is characteristic of protein misfolding, [10] the native cell proteasome may recognize and degrade proteins tagged with the hydrophobic moiety. Taavi Neklesa and Craig Crews first reported hydrophobic tag degradation in 2011 as a tool to probe protein function in conjunction with cognate HaloTag fusion proteins. [11] This principle has also been further used to effectively degrade transcription factors [12] (a traditionally difficult class to drug [13] ) and cancer-linked EZH2 in in vitro models. [14] As of yet, no drug candidates have been publicly identified making use of this technology.

Additional use cases

Lysosome-targeting chimeras (LYTACs) have been developed, combining target-binding compounds or antibodies and glycopeptide ligands to stimulate the lysosomal degradation pathway. Unlike the proteasome pathway, this enables the targeted degradation of extracellular and membrane-bound proteins in addition to cytoplasmic ones. [15] Autophagy-targeting chimeras (AUTACs) can be employed to degrade proteins as well as protein aggregates and organelles. [16] AUTAC degradation tags are typically derived from guanine though the particular mechanism of action is still unclear. [17] Autophagosome-tethering compounds (ATTECs) mimic this strategy, directly appending a target protein to the autophagosome membrane for degradation absent the use of a linker. [18] Phosphorylation-inducing chimeric small molecules (PHICS) employ the warhead-linker-recruiter structure to direct phosphorylation of a given target by proximity to a desired kinase. This technique does not necessarily involve protein degradation and may instead be used to modulate protein function to direct or inhibit certain pathways. [19] Further work in the Crews Lab has used chimeric oligonucleotides, the dCas9 protein, and chimeric small molecules to create the TRAFTAC system for generalizable transcription factor degradation. [20]

Advantages

The ability to inhibit or modify enzyme function absent a catalytic pocket binding site target greatly expands the potentially druggable portion of the proteome. [21] Furthermore, most classes of chimeric small molecules can act on many targets over their life cycle, [22] lowering the effective dose compared to traditional inhibitors that act only on one protein at a time. [23] These therapeutics provide an alternative mechanism of action that may be useful as a combination therapy in diseases where drug resistance is a concern. [24] Chimeric drug activity is also highly dependent on distance between targeted proteins [25] allowing effect to be effectively tuned through optimization of the linker structure.

Challenges

The existence of two or more binding domains increases the difficulty of synthesis for chimeric molecules. Each component must be discovered, optimized, and synthesized in such a way that they can be linked together, driving up cost relative to single-domain inhibitors. The large size of chimeric molecules (typically 700-1100 Da) makes effective delivery difficult and increases complexity in pharmacokinetic design. [26] [27] Care must be taken to ensure that the molecule is capable of passing through the cell membrane [28] and subsisting long enough to have therapeutic effect. Additionally, protein-protein ternary complexes are generally unstable, adding to the difficulty of chimeric drug design [29]

Related Research Articles

<span class="mw-page-title-main">Proteasome</span> Protein complexes which degrade unnecessary or damaged proteins by proteolysis

Proteasomes are protein complexes which degrade unneeded or damaged proteins by proteolysis, a chemical reaction that breaks peptide bonds. Enzymes that help such reactions are called proteases.

In molecular biology and pharmacology, a small molecule or micromolecule is a low molecular weight organic compound that may regulate a biological process, with a size on the order of 1 nm. Many drugs are small molecules; the terms are equivalent in the literature. Larger structures such as nucleic acids and proteins, and many polysaccharides are not small molecules, although their constituent monomers are often considered small molecules. Small molecules may be used as research tools to probe biological function as well as leads in the development of new therapeutic agents. Some can inhibit a specific function of a protein or disrupt protein–protein interactions.

<span class="mw-page-title-main">Binding site</span> Molecule-specific coordinate bonding area in biological systems

In biochemistry and molecular biology, a binding site is a region on a macromolecule such as a protein that binds to another molecule with specificity. The binding partner of the macromolecule is often referred to as a ligand. Ligands may include other proteins, enzyme substrates, second messengers, hormones, or allosteric modulators. The binding event is often, but not always, accompanied by a conformational change that alters the protein's function. Binding to protein binding sites is most often reversible, but can also be covalent reversible or irreversible.

A hormone receptor is a receptor molecule that binds to a specific hormone. Hormone receptors are a wide family of proteins made up of receptors for thyroid and steroid hormones, retinoids and Vitamin D, and a variety of other receptors for various ligands, such as fatty acids and prostaglandins. Hormone receptors are of mainly two classes. Receptors for peptide hormones tend to be cell surface receptors built into the plasma membrane of cells and are thus referred to as trans membrane receptors. An example of this is Actrapid. Receptors for steroid hormones are usually found within the protoplasm and are referred to as intracellular or nuclear receptors, such as testosterone. Upon hormone binding, the receptor can initiate multiple signaling pathways, which ultimately leads to changes in the behavior of the target cells.

<span class="mw-page-title-main">Ubiquitin ligase</span> Protein

A ubiquitin ligase is a protein that recruits an E2 ubiquitin-conjugating enzyme that has been loaded with ubiquitin, recognizes a protein substrate, and assists or directly catalyzes the transfer of ubiquitin from the E2 to the protein substrate. In simple and more general terms, the ligase enables movement of ubiquitin from a ubiquitin carrier to another thing by some mechanism. The ubiquitin, once it reaches its destination, ends up being attached by an isopeptide bond to a lysine residue, which is part of the target protein. E3 ligases interact with both the target protein and the E2 enzyme, and so impart substrate specificity to the E2. Commonly, E3s polyubiquitinate their substrate with Lys48-linked chains of ubiquitin, targeting the substrate for destruction by the proteasome. However, many other types of linkages are possible and alter a protein's activity, interactions, or localization. Ubiquitination by E3 ligases regulates diverse areas such as cell trafficking, DNA repair, and signaling and is of profound importance in cell biology. E3 ligases are also key players in cell cycle control, mediating the degradation of cyclins, as well as cyclin dependent kinase inhibitor proteins. The human genome encodes over 600 putative E3 ligases, allowing for tremendous diversity in substrates.

<span class="mw-page-title-main">P-glycoprotein</span> Mammalian protein found in Homo sapiens

P-glycoprotein 1 also known as multidrug resistance protein 1 (MDR1) or ATP-binding cassette sub-family B member 1 (ABCB1) or cluster of differentiation 243 (CD243) is an important protein of the cell membrane that pumps many foreign substances out of cells. More formally, it is an ATP-dependent efflux pump with broad substrate specificity. It exists in animals, fungi, and bacteria, and it likely evolved as a defense mechanism against harmful substances.

Heterogeneous nuclear ribonucleoproteins (hnRNPs) are complexes of RNA and protein present in the cell nucleus during gene transcription and subsequent post-transcriptional modification of the newly synthesized RNA (pre-mRNA). The presence of the proteins bound to a pre-mRNA molecule serves as a signal that the pre-mRNA is not yet fully processed and therefore not ready for export to the cytoplasm. Since most mature RNA is exported from the nucleus relatively quickly, most RNA-binding protein in the nucleus exist as heterogeneous ribonucleoprotein particles. After splicing has occurred, the proteins remain bound to spliced introns and target them for degradation.

<span class="mw-page-title-main">SCF complex</span>

Skp, Cullin, F-box containing complex is a multi-protein E3 ubiquitin ligase complex that catalyzes the ubiquitination of proteins destined for 26S proteasomal degradation. Along with the anaphase-promoting complex, SCF has important roles in the ubiquitination of proteins involved in the cell cycle. The SCF complex also marks various other cellular proteins for destruction.

Phosphodiesterase 1, PDE1, EC 3.1.4.1, systematic name oligonucleotide 5′-nucleotidohydrolase) is a phosphodiesterase enzyme also known as calcium- and calmodulin-dependent phosphodiesterase. It is one of the 11 families of phosphodiesterase (PDE1-PDE11). Phosphodiesterase 1 has three subtypes, PDE1A, PDE1B and PDE1C which divide further into various isoforms. The various isoforms exhibit different affinities for cAMP and cGMP.

<span class="mw-page-title-main">Fusion protein</span> Protein created by joining other proteins into a single polypeptide

Fusion proteins or chimeric (kī-ˈmir-ik) proteins are proteins created through the joining of two or more genes that originally coded for separate proteins. Translation of this fusion gene results in a single or multiple polypeptides with functional properties derived from each of the original proteins. Recombinant fusion proteins are created artificially by recombinant DNA technology for use in biological research or therapeutics. Chimeric or chimera usually designate hybrid proteins made of polypeptides having different functions or physico-chemical patterns. Chimeric mutant proteins occur naturally when a complex mutation, such as a chromosomal translocation, tandem duplication, or retrotransposition creates a novel coding sequence containing parts of the coding sequences from two different genes. Naturally occurring fusion proteins are commonly found in cancer cells, where they may function as oncoproteins. The bcr-abl fusion protein is a well-known example of an oncogenic fusion protein, and is considered to be the primary oncogenic driver of chronic myelogenous leukemia.

The unfolded protein response (UPR) is a cellular stress response related to the endoplasmic reticulum (ER) stress. It has been found to be conserved between mammalian species, as well as yeast and worm organisms.

Proteostasis is the dynamic regulation of a balanced, functional proteome. The proteostasis network includes competing and integrated biological pathways within cells that control the biogenesis, folding, trafficking, and degradation of proteins present within and outside the cell. Loss of proteostasis is central to understanding the cause of diseases associated with excessive protein misfolding and degradation leading to loss-of-function phenotypes, as well as aggregation-associated degenerative disorders. Therapeutic restoration of proteostasis may treat or resolve these pathologies.

<span class="mw-page-title-main">Hsp90 inhibitor</span> Drug class

An Hsp90 inhibitor is a substance that inhibits that activity of the Hsp90 heat shock protein. Since Hsp90 stabilizes a variety of proteins required for survival of cancer cells, these substances may have therapeutic benefit in the treatment of various types of malignancies. Furthermore, a number of Hsp90 inhibitors are currently undergoing clinical trials for a variety of cancers. Hsp90 inhibitors include the natural products geldanamycin and radicicol as well as semisynthetic derivatives 17-N-Allylamino-17-demethoxygeldanamycin (17AAG).

A selective estrogen receptor degrader or downregulator (SERD) is a type of drug which binds to the estrogen receptor (ER) and, in the process of doing so, causes the ER to be degraded and thus downregulated. They are used to treat estrogen receptor-sensitive or progesterone receptor-sensitive breast cancer, along with older classes of drugs like selective estrogen receptor modulators (SERMs) and aromatase inhibitors.

Kang-Yell Choi is a professor of biotechnology at Yonsei University, and has a joint appointment position as a CEO of CK Regeon Inc. in Seoul, Korea. He has been performing researches related to cellular signaling, especially for the Wnt/β-catenin pathway involving various pathophysiologies. Choi has been leading the Translational Research Center for Protein Function Control (TRCP), a Korean government supported drug development institute, as a director for 10 years. Choi has been carrying out R&D to develop agents controlling the Wnt/β-catenin signaling pathway. Choi's main interest is development of the agents to treat intractable diseases that suppress tissue regeneration system through overexpression of CXXC5 and subsequent suppression of the Wnt/β-catenin signaling.

Craig M. Crews is an American scientist at Yale University known for his contributions to chemical biology. He is known for his contributions to the field of induced proximity through his work in creating heterobifunctional molecules that hijack cellular processes by inducing the interaction of two proteins inside a living cell. His initial work focused on the discovery of PROteolysis-TArgeting Chimeras (PROTACs) to trigger degradation of disease-causing proteins, a process known as targeted protein degradation (TPD), and he has since developed new versions of -TACs to leverage other cellular processes and protein families to treat disease.

A proteolysis targeting chimera (PROTAC) is a heterobifunctional molecule composed of two active domains and a linker, capable of removing specific unwanted proteins. Rather than acting as a conventional enzyme inhibitor, a PROTAC works by inducing selective intracellular proteolysis. PROTACs consist of two covalently linked protein-binding molecules: one capable of engaging an E3 ubiquitin ligase, and another that binds to a target protein meant for degradation. Recruitment of the E3 ligase to the target protein results in ubiquitination and subsequent degradation of the target protein via the proteasome. Because PROTACs need only to bind their targets with high selectivity, there are currently many efforts to retool previously ineffective inhibitor molecules as PROTACs for next-generation drugs.

<span class="mw-page-title-main">Daniel Nomura</span>

Daniel K. Nomura is an American chemical biologist and Professor of Chemical Biology and Molecular Therapeutics at the University of California, Berkeley, in the Departments of Chemistry and Molecular & Cell Biology. His work employs chemoproteomic approaches to develop small molecule therapeutics and therapeutic modalities against traditionally "undruggable" proteins.

A molecular glue is a small molecule that induces the interaction between two proteins that do not normally interact.

James Allen Wells is a Professor of Pharmaceutical Chemistry and Cellular & Molecular Pharmacology at the University of California, San Francisco (UCSF) and a member of the National Academy of Sciences. He received his B.A. degrees in biochemistry and psychology from University of California, Berkeley in 1973 and a PhD in biochemistry from Washington State University with Ralph Yount, PhD in 1979. He completed his postdoctoral studies at Stanford University School of Medicine with George Stark in 1982. He is a pioneer in protein engineering, phage display, fragment-based lead discovery, cellular apoptosis, and the cell surface proteome.

References

  1. ↑ Veber, Daniel F.; Johnson, Stephen R.; Cheng, Hung-Yuan; Smith, Brian R.; Ward, Keith W.; Kopple, Kenneth D. (2002-06-01). "Molecular Properties That Influence the Oral Bioavailability of Drug Candidates". Journal of Medicinal Chemistry. 45 (12): 2615–2623. doi:10.1021/jm020017n. ISSN   0022-2623. PMID   12036371 . Retrieved 2023-04-14.
  2. ↑ Li, Qingxin; Kang, CongBao (2020-07-24). "Mechanisms of Action for Small Molecules Revealed by Structural Biology in Drug Discovery". International Journal of Molecular Sciences. 21 (15): 5262. doi: 10.3390/ijms21155262 . ISSN   1422-0067. PMC   7432558 . PMID   32722222.
  3. ↑ Kana, Omar; Brylinski, Michal (May 2019). "Elucidating the druggability of the human proteome with eFindSite". Journal of Computer-aided Molecular Design. 33 (5): 509–519. Bibcode:2019JCAMD..33..509K. doi:10.1007/s10822-019-00197-w. ISSN   0920-654X. PMC   6516084 . PMID   30888556.
  4. ↑ Li, Haobin; Dong, Jinyun; Cai, Maohua; Xu, Zhiyuan; Cheng, Xiang-Dong; Qin, Jiang-Jiang (2021-09-06). "Protein degradation technology: a strategic paradigm shift in drug discovery". Journal of Hematology & Oncology. 14 (1): 138. doi: 10.1186/s13045-021-01146-7 . ISSN   1756-8722. PMC   8419833 . PMID   34488823. S2CID   237418638.
  5. ↑ Li, Haobin; Dong, Jinyun; Cai, Maohua; Xu, Zhiyuan; Cheng, Xiang-Dong; Qin, Jiang-Jiang (2021-09-06). "Protein degradation technology: a strategic paradigm shift in drug discovery". Journal of Hematology & Oncology. 14 (1): 138. doi: 10.1186/s13045-021-01146-7 . ISSN   1756-8722. PMC   8419833 . PMID   34488823. S2CID   237418638.
  6. ↑ Sakamoto, Kathleen M.; Kim, Kyung B.; Kumagai, Akiko; Mercurio, Frank; Crews, Craig M.; Deshaies, Raymond J. (2001-07-17). "Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation". Proceedings of the National Academy of Sciences of the United States of America. 98 (15): 8554–8559. Bibcode:2001PNAS...98.8554S. doi: 10.1073/pnas.141230798 . ISSN   0027-8424. PMC   37474 . PMID   11438690.
  7. ↑ Bouchie, Aaron; Allison, Malorye; Webb, Sarah; DeFrancesco, Laura (March 2014). "Nature Biotechnology's academic spinouts of 2013". Nature Biotechnology. 32 (3): 229–238. doi:10.1038/nbt.2846. ISSN   1546-1696. PMID   24727773. S2CID   692896 . Retrieved 2023-04-14.
  8. ↑ "PROTAC Protein Degrader Pipeline | Arvinas" . Retrieved 2023-04-14.
  9. ↑ "Pfizer Strengthens Cancer Standing with Protein Degrader Collaboration". BioSpace. Retrieved 2023-04-14.
  10. ↑ Fredrickson, Eric K.; Rosenbaum, Joel C.; Locke, Melissa N.; Milac, Thomas I.; Gardner, Richard G. (2011-07-01). "Exposed hydrophobicity is a key determinant of nuclear quality control degradation". Molecular Biology of the Cell. 22 (13): 2384–2395. doi:10.1091/mbc.E11-03-0256. ISSN   1059-1524. PMC   3128539 . PMID   21551067.
  11. ↑ Neklesa, Taavi K.; Tae, Hyun Seop; Schneekloth, Ashley R.; Stulberg, Michael J.; Corson, Timothy W.; Sundberg, Thomas B.; Raina, Kanak; Holley, Scott A.; Crews, Craig M. (2011-07-03). "Small-Molecule Hydrophobic Tagging Induced Degradation of HaloTag Fusion Proteins". Nature Chemical Biology. 7 (8): 538–543. doi:10.1038/nchembio.597. ISSN   1552-4450. PMC   3139752 . PMID   21725302.
  12. ↑ Choi, So Ra; Wang, Hee Myeong; Shin, Min Hyeon; Lim, Hyun-Suk (2021-06-15). "Hydrophobic Tagging-Mediated Degradation of Transcription Coactivator SRC-1". International Journal of Molecular Sciences. 22 (12): 6407. doi: 10.3390/ijms22126407 . ISSN   1422-0067. PMC   8232704 . PMID   34203850.
  13. ↑ Lambert, Samuel A.; Jolma, Arttu; Campitelli, Laura F.; Das, Pratyush K.; Yin, Yimeng; Albu, Mihai; Chen, Xiaoting; Taipale, Jussi; Hughes, Timothy R.; Weirauch, Matthew T. (2018-02-08). "The Human Transcription Factors". Cell. 172 (4): 650–665. doi: 10.1016/j.cell.2018.01.029 . ISSN   0092-8674. PMID   29425488. S2CID   3599827 . Retrieved 2023-04-14.
  14. ↑ Ma, Anqi; Stratikopoulos, Elias; Park, Kwang-Su; Wei, Jieli; Martin, Tiphaine C.; Yang, Xiaobao; Schwarz, Megan; Leshchenko, Violetta; Rialdi, Alexander; Dale, Brandon; Lagana, Alessandro; Guccione, Ernesto; Parekh, Samir; Parsons, Ramon; Jin, Jian (February 2020). "Discovery of a first-in-class EZH2 selective degrader". Nature Chemical Biology. 16 (2): 214–222. doi:10.1038/s41589-019-0421-4. ISSN   1552-4469. PMC   6982609 . PMID   31819273.
  15. ↑ Banik, Steven; Pedram, Kayvon; Wisnovsky, Simon; Riley, Nicholas; Bertozzi, Carolyn (2019). "Lysosome Targeting Chimeras (LYTACs) for the Degradation of Secreted and Membrane Proteins | Biological and Medicinal Chemistry". ChemRxiv. Cambridge Open Engage. doi:10.26434/chemrxiv.7927061.v1 . Retrieved 2023-04-14.
  16. ↑ Takahashi, Daiki; Moriyama, Jun; Nakamura, Tomoe; Miki, Erika; Takahashi, Eriko; Sato, Ayami; Akaike, Takaaki; Itto-Nakama, Kaori; Arimoto, Hirokazu (2019-12-05). "AUTACs: Cargo-Specific Degraders Using Selective Autophagy". Molecular Cell. 76 (5): 797–810.e10. doi: 10.1016/j.molcel.2019.09.009 . ISSN   1097-4164. PMID   31606272. S2CID   204546213.
  17. ↑ Ding, Yu; Fei, Yiyan; Lu, Boxun (July 2020). "Emerging New Concepts of Degrader Technologies". Trends in Pharmacological Sciences. 41 (7): 464–474. doi:10.1016/j.tips.2020.04.005. ISSN   1873-3735. PMC   7177145 . PMID   32416934.
  18. ↑ Li, Zhaoyang; Zhu, Chenggang; Ding, Yu; Fei, Yiyan; Lu, Boxun (January 2020). "ATTEC: a potential new approach to target proteinopathies". Autophagy. 16 (1): 185–187. doi:10.1080/15548627.2019.1688556. ISSN   1554-8635. PMC   6984452 . PMID   31690177.
  19. ↑ Siriwardena, Sachini U.; Munkanatta Godage, Dhanushka N. P.; Shoba, Veronika M.; Lai, Sophia; Shi, Mengchao; Wu, Peng; Chaudhary, Santosh K.; Schreiber, Stuart L.; Choudhary, Amit (2020-08-19). "Phosphorylation-Inducing Chimeric Small Molecules". Journal of the American Chemical Society. 142 (33): 14052–14057. doi:10.1021/jacs.0c05537. ISSN   0002-7863. PMID   32787262. S2CID   221125004 . Retrieved 2023-04-14.
  20. ↑ Samarasinghe, Kusal T. G.; Jaime-Figueroa, Saul; Burgess, Michael; Nalawansha, Dhanusha A.; Dai, Katherine; Hu, Zhenyi; Bebenek, Adrian; Holley, Scott A.; Crews, Craig M. (2021-05-20). "Targeted degradation of transcription factors by TRAFTACs: TRAnscription Factor TArgeting Chimeras". Cell Chemical Biology. 28 (5): 648–661.e5. doi:10.1016/j.chembiol.2021.03.011. ISSN   2451-9448. PMC   8524358 . PMID   33836141.
  21. ↑ Lu, Bin; Ye, Jianpin (October 2021). "Commentary: PROTACs make undruggable targets druggable: Challenge and opportunity". Acta Pharmaceutica Sinica B. 11 (10): 3335–3336. doi:10.1016/j.apsb.2021.07.017. ISSN   2211-3835. PMC   8546888 . PMID   34729320.
  22. ↑ Békés, Miklós; Langley, David R.; Crews, Craig M. (March 2022). "PROTAC targeted protein degraders: the past is prologue". Nature Reviews Drug Discovery. 21 (3): 181–200. doi:10.1038/s41573-021-00371-6. ISSN   1474-1784. PMC   8765495 . PMID   35042991.
  23. ↑ Yao, Tingting; Xiao, Heng; Wang, Hong; Xu, Xiaowei (2022-09-07). "Recent Advances in PROTACs for Drug Targeted Protein Research". International Journal of Molecular Sciences. 23 (18): 10328. doi: 10.3390/ijms231810328 . ISSN   1422-0067. PMC   9499226 . PMID   36142231.
  24. ↑ Burke, Matthew R.; Smith, Alexis R.; Zheng, Guangrong (2022). "Overcoming Cancer Drug Resistance Utilizing PROTAC Technology". Frontiers in Cell and Developmental Biology. 10: 872729. doi: 10.3389/fcell.2022.872729 . ISSN   2296-634X. PMC   9083012 . PMID   35547806.
  25. ↑ Cyrus, Kedra; Wehenkel, Marie; Choi, Eun-Young; Han, Hyeong-Jun; Lee, Hyosung; Swanson, Hollie; Kim, Kyung-Bo (February 2011). "Impact of linker length on the activity of PROTACs". Molecular BioSystems. 7 (2): 359–364. doi:10.1039/c0mb00074d. ISSN   1742-2051. PMC   3835402 . PMID   20922213.
  26. ↑ Cantrill, Carina; Chaturvedi, Prasoon; Rynn, Caroline; Petrig Schaffland, Jeannine; Walter, Isabelle; Wittwer, Matthias B. (2020-06-01). "Fundamental aspects of DMPK optimization of targeted protein degraders". Drug Discovery Today. 25 (6): 969–982. doi:10.1016/j.drudis.2020.03.012. ISSN   1359-6446. PMID   32298797. S2CID   215803460 . Retrieved 2023-04-14.
  27. ↑ Pike, Andy; Williamson, Beth; Harlfinger, Stephanie; Martin, Scott; McGinnity, Dermot F. (2020-10-01). "Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective". Drug Discovery Today. 25 (10): 1793–1800. doi:10.1016/j.drudis.2020.07.013. ISSN   1359-6446. PMID   32693163. S2CID   220699596 . Retrieved 2023-04-14.
  28. ↑ Klein, Victoria G.; Townsend, Chad E.; Testa, Andrea; Zengerle, Michael; Maniaci, Chiara; Hughes, Scott J.; Chan, Kwok-Ho; Ciulli, Alessio; Lokey, R. Scott (10 September 2020). "Understanding and Improving the Membrane Permeability of VH032-Based PROTACs | ACS Medicinal Chemistry Letters". ACS Medicinal Chemistry Letters. 11 (9): 1732–1738. doi:10.1021/acsmedchemlett.0c00265. PMC   7488288 . PMID   32939229.
  29. ↑ Weiss, Dahlia R.; Bortolato, Andrea; Sun, Yongnian; Cai, Xianmei; Lai, Chon; Guo, Sixuan; Shi, Lihong; Shanmugasundaram, Veerabahu (2023-04-10). "On Ternary Complex Stability in Protein Degradation: In Silico Molecular Glue Binding Affinity Calculations". Journal of Chemical Information and Modeling. 63 (8): 2382–2392. doi:10.1021/acs.jcim.2c01386. ISSN   1549-9596. PMID   37037192. S2CID   258061404 . Retrieved 2023-04-14.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.